Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder

Neuropsychopharmacology

Volumn 32, Issue 1, 2007, Pages 153-161

  Landén, Mikael ^a   Nissbrandt, Hans ^b   Allgulander, Christer ^a   Sörvik, Karin ^b   Ysander, Christina ^b   Eriksson, Elias ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Controlled clinical trial; Paroxetine; Premenstrual syndrome; Serotonin reuptake inhibitors

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENTAL INSTABILITY; MOOD; MULTICENTER STUDY; NAUSEA; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SWEATING; SYMPTOM; TREATMENT INDICATION; XEROSTOMIA;

ADULT; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PAIN MEASUREMENT; PAROXETINE; PLACEBOS; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33845702468     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301216     Document Type: Article

References (46)

1. Angst J, Sellaro R, Merikangas KR, Endicott J (2001). The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 104: 110-116.
2. Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378-383.
3. Black K, Shea C, Dursun S, Kutcher S (2000). Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 25: 255-261.
4. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R (1999). Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 14: 681-685.
5. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K et al (2002). Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 100: 435-444.
6. Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M (2004). Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med 66: 707-713.
7. Eriksson E, Andersch B, Ho HP, Landén M, Sundblad C (2002). Diagnosis and treatment of premenstrual dysphoria. J Clin Psychiatry 63: 16-23.
8. Eriksson E, Hedberg MA, Andersch B, Sundblad C (1995). The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12: 167-176.
9. Eriksson E, Lisj P, Sundblad C, Andersson K, Andersch B, Modigh K (1990). Effect of clomipramine on premenstrual syndrome. Acta Psychiatr Scand 81: 87-88.
10. Freeman EW (2003). Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 28(Suppl 3): 25-37.
11. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S (2004). Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161: 343-351.
12. Guy W (1976). ECDEU Assessment manual for psychopharmacology: Publication ADM 76-338. US Department of Health, Education, and Welfare Publications: Washington, DC.
13. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L (2002). Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 100: 1219-1229.
14. Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28(Suppl 3): 1-23.
15. Halbreich U, Smoller JW (1997). Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 58: 399-402.
16. Hartlage SA, Arduino KE (2002). Toward the content validity of premenstrual dysphoric disorder: do anger and irritability more than depressed mood represent treatment-seekers' experiences? Psychol Rep 90: 189-202.
17. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ (1999). Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Family Med 8: 328-332.
18. Landén M, Eriksson E (2003). How does premenstrual dysphoria relate to anxiety disorders? Depression Anxiety 17: 122-129.
19. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M (2002). Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 24: 417-433.
20. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
21. Muller U, Murai T, Bauer-Wittmund T, von Cramon DY (1999). Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 13: 805-811.
22. Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS (1998). Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 10: 453-455.
23. Parry BL (2001). The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications. CNS Drugs 15: 277-285.
24. Pearlstein T (2002). Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs 62: 1869-1885.
25. Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E et al (2000). Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 61: 101-109.
26. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11(Suppl 3): 89-95.
27. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33; quiz 34-57.
28. Sloan RL, Brown KW, Pentland B (1992). Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj 6: 315-319.
29. Steiner M, Born L (2000). Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 15(Suppl 3): S5-S17.
30. Steiner M, Brown E, Trzepacz P, Dillon J, Berger C, Carter D et al (2003). Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Women Ment Health 6: 71-77.
31. Steiner M, Haskett RF, Carroll BJ (1980). Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 62: 177-190.
32. Steiner M, Korzekwa M, Lamont J, Wilkins A (1997). Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 33: 771-774.
33. Steiner M, Romano SJ, Babcock S, Dillon J, Shuler C, Berger C et al (2001). The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. Bjog 108: 462-468.
34. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R et al (1995). Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 332: 1529-1534.
35. Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee MD, Van Erp E (2005). Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 193: 352-360.
36. Stone AB, Pearlstein TB, Brown WA (1991). Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 52: 290-293.
37. Su TP, Schmidt PJ, Danaceau MA, Tobin MB, Rosenstein DL, Murphy DL et al (1997). Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 16: 346-356.
38. Sundblad C, Hedberg MA, Eriksson E (1993). Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9: 133-145.
39. Sundblad C, Modigh K, Andersch B, Eriksson E (1992). Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 85: 39-47.
40. van Elteren PH (1960). On the combination of independent two-sample test of Wilcoxon. Bull Int Stat Inst 37: 351-361.
41. van Leusden HA (1995). Premenstrual syndrome no progesterone; premenstrual dysphoric disorder no serotonin deficiency. Lancet 346: 1443-1444.
42. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F et al (1998). Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 18: 390-398.
43. Wittchen HU, Becker E, Lieb R, Krause P (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32: 119-132.
44. Wyatt KM, Dimmock PW, O'Brien PMS (2002). Selective serotonin reuptake inhibitors for premenstrual syndrome (Cochrane Review). Cochrane Database Syst Rev, Issue 3. Art. No.: CD001396. DOI:10.1002/14651858.CD001396.
45. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E et al (1997). Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 278: 983-988.
46. Young SA, Hurt PH, Benedek DM, Howard RS (1998). Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 59: 76-80.